We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

This study has been terminated.
(Voluntary halt due to an FDA Clinical Hold issued in relation to DV2-HBV-10.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00498212
First Posted: July 9, 2007
Last Update Posted: August 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dynavax Technologies Corporation
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2008
  Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: June 16, 2014